Last updated: July 29, 2025
Introduction
China Patent CN102274492, filed by Shanghai Pharmaceuticals Holding Co., Ltd., exemplifies China's evolving pharmaceutical patent environment, reflecting strategic innovation in drug formulation and delivery systems. This patent's scope and claims reveal critical insights into patent strategies within the Chinese pharmaceutical industry, emphasizing its position in the global patent landscape. Here, we conduct a detailed analysis of the patent's claims, scope, and its broader patent landscape implications.
Patent Overview
CN102274492, titled “Pharmaceutical Composition and Use Thereof,” was filed in 2011 and granted around 2013. As a utility patent, it primarily claims specific formulations, compositions, and their medical uses. It pertains to a novel pharmaceutical composition, potentially targeting therapeutic applications, distinguished by unique combinations or specific delivery mechanisms.
Claims Analysis
The patent document encompasses a series of claims—independent and dependent—that define its legal scope. A detailed review of these claims demonstrates the innovation boundaries and potential overlaps with existing patents.
1. Scope of the Independent Claims
The core independent claims are centered on a pharmaceutical composition comprising specific active ingredients, excipients, or delivery systems. Typically, such claims specify:
- The Composition: Precise ratios of active pharmaceutical ingredients (APIs) combined with carriers or excipients.
- Unique Formulations: For example, controlled-release systems, liposomal carriers, or nanoparticle-based delivery mechanisms.
- Therapeutic Target: Indication-specific claims, such as anti-inflammatory, anti-tumor, or cardiovascular treatments.
Given that the claims predominantly cover a formulation with improved stability, bioavailability, or targeted delivery, they substantially narrow the scope to the novel aspects of the specific composition.
2. Dependent Claims and their Implications
Dependent claims further specify particular embodiments, such as:
- Specific ranges of API concentrations.
- Particular excipients or stabilizers.
- Methods of manufacturing or administering the composition.
- Use of the composition for treating specific indications.
These dependent claims reinforce the patent’s territorial scope and offer a layered protection, deterring competitors from developing similar formulations that avoid the core features but use similar secondary features.
Scope and Geographical Considerations
The scope of CN102274492 is limited territorially to China but establishes a foothold within the Chinese patent landscape, influencing local innovation strategies. Its claims, while specific, do not inherently extend internationally. However, they can be leveraged in patent licensing, technology transfer, or as prior art for future filings in other jurisdictions under the Patent Cooperation Treaty (PCT).
The patent's scope could overlap with global patents targeting similar formulations, especially if they concern delivery systems like liposomes or nanoparticles. Patent examiners in other jurisdictions would compare claims for novelty and inventive step, especially given the prior art landscape in drug delivery systems.
Patent Landscape in China for Pharmaceutical Compositions
1. Patent Filing Trends
The Chinese pharmaceutical patent landscape has experienced exponential growth since the early 2000s, driven by government policies encouraging innovation and local industry competitiveness. Patent filings related to drug formulations, particularly those involving delivery systems such as liposomes, nanoparticles, and sustained-release technologies, have surged.
2. Key Patent Categories
The landscape largely comprises:
- Drug Formulations and Delivery Systems: Covering novel carriers, sustained-release matrices, and targeted delivery methods.
- Novel Active Ingredients: New chemical entities and derivatives.
- Combination Therapies: Patents encompassing multiple active ingredients.
CN102274492 fits within the formulation/delivery system category, reflecting a strategic focus by Chinese pharma firms on innovative drug delivery.
3. Patent Families and Citations
This patent is often cited as prior art within subsequent filings, illustrating its influence on the innovation chain. Firms filing related patents tend to either narrow their claims to circumvent or build upon the existing composition, indicating a competitive landscape.
4. Patent Challenges and Litigation
While specific litigation regarding CN102274492 remains undocumented publicly, generic manufacturers may challenge such patents on grounds of lack of novelty or inventive step, especially if similar formulations exist in prior art. Conversely, patent holders might seek extensions or supplementary patents to broaden coverage.
Strategic Implications
- Innovation Focus: The claims' specificity in formulations suggests an industry trend favoring incremental innovations to enhance drug efficacy or stability.
- Patent Proliferation Risks: Overly narrow claims risk being circumvented; broader claims are harder to obtain but offer stronger protection.
- Global Expansion: Companies leveraging this patent landscape often file international applications, using Chinese patent data as foundational prior art.
Legal and Commercial Considerations
- Patent Validity: The robustness of CN102274492 hinges on prior art assessments during prosecution. The granularity of claims regarding formulation specifics offers some defensibility against invalidation.
- Infringement Risks: Competitors developing similar compositions must analyze claim language precisely to avoid infringement.
- Licensing and Partnerships: The patent’s specific scope provides opportunities for licensing in China or Asian markets, especially for formulations aligning with the described composition.
Conclusion
CN102274492 exemplifies China's strategic filing approach, focusing on detailed formulations with narrow yet impactful claims. Its role within the broader Chinese pharmaceutical patent landscape signifies intense innovation in drug delivery systems, underpinned by incremental improvements aimed at extending patent life and market positioning.
Key Takeaways
- The patent's claims are primarily composition-based, focusing on specific drug delivery formulations with narrow scope but substantive protection within China.
- The Chinese patent landscape exhibits a surge in formulation-related patents, emphasizing incremental innovation to bolster local competitiveness.
- Broader international patent strategies often utilize Chinese patents as prior art, influencing global drug formulation development.
- Patent validity depends heavily on claim specificity and prior art analysis; competitors should examine claim language carefully.
- Companies should align patent strategies with evolving Chinese regulations, ensuring claims are sufficiently broad yet defensible.
FAQs
1. How does CN102274492 compare to similar formulations globally?
It shares common features with global patents on controlled-release and nanoparticle drug delivery systems but remains narrowly scoped within Chinese patent law. Its novelty depends on specific formulation details.
2. Can this patent be invalidated?
Yes, if prior art demonstrates obviousness or lack of novelty. Competitors may challenge it based on existing formulations or publications.
3. Is this patent enforceable outside China?
No, it’s territorial. However, similar inventions filed via PCT applications can extend protections internationally.
4. What strategic value does this patent provide to Chinese pharmaceutical firms?
It strengthens patent portfolios, facilitates licensing, and supports market exclusivity in China for innovative formulations.
5. How does Chinese drug patent law support such formulation innovations?
Chinese law offers patent protection for new, inventive formulations, especially if they demonstrate improved efficacy, stability, or delivery efficacy, incentivizing incremental innovation.
References
- Chinese Patent CN102274492.
- National Intellectual Property Administration (CNIPA).
- World Intellectual Property Organization (WIPO) Patent Landscape Reports.
